LEXINGTON, Mass.--(BUSINESS WIRE)--Synageva BioPharma Corp., a privately held biopharmaceutical company, announced today that it has been invited to present at the upcoming 29th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2011, at 9:30 AM Pacific Standard Time/12:30 PM Eastern Standard Time at the Westin St. Francis Hotel in San Francisco, CA. Sanj K. Patel, President & CEO of Synageva BioPharma, will provide an overview of both the Company and its lead program, SBC-102, an enzyme replacement therapy in development to treat Lysosomal Acid Lipase (LAL) Deficiency, also known as Wolman Disease and Cholesteryl Ester Storage Disease (CESD), a condition for which there are no approved treatments.
